[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621359":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":33,"locations":42,"responsibleParty":105,"collaborators":10,"id":108,"slug":10,"hasResults":109,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":10,"eligibilityCriteria":113,"healthyVolunteers":109,"sex":114,"minAge":115,"maxAge":10,"enrollmentInfo":116,"targetDuration":10,"studyType":119,"phases":10,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},{"fullName":5,"class":6},"University of Malaya","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Normal dose group",null,"Patients receiving standard dose of chemotherapy",[13,14],"Other: Progression free survival","Other: Overall survival",{"label":16,"type":10,"description":17,"interventionNames":18},"Dose reduction group","Patients receiving lower doses of chemotherapy",[13,14],[20,24],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"Progression free survival","PFS",[16,9],{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"Overall survival","OS",[16,9],[29],{"name":30,"affiliation":31,"role":32},"Mau Ern Poh, MBBS","Universiti Malaya","PRINCIPAL_INVESTIGATOR",[34,38],{"name":30,"role":35,"phone":36,"phoneExt":10,"email":37},"CONTACT","+60379494422","ernestpoh@um.edu.my",{"name":39,"role":35,"phone":40,"phoneExt":10,"email":41},"Danouska Bala Krishnan","+603-79492351","danouska@ummc.edu.my",[43,61,78,93],{"facility":44,"status":45,"city":46,"state":10,"zip":10,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Queen Mary Hospital, The University of Hong Kong","RECRUITING","Hong Kong","HK",{"type":49,"coordinates":50},"Point",[51,52],114.17469,22.27832,{"lat":52,"lon":51},[55,59],{"name":56,"role":35,"phone":57,"phoneExt":10,"email":58},"Wang Chun Kwok","+85222556208","kwokwch@hku.hk",{"name":60,"role":32,"phone":10,"phoneExt":10,"email":10},"Chun Kwok Wang",{"facility":62,"status":45,"city":63,"state":64,"zip":10,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Hospital Tengku Ampuan Afzan","Kuantan","Pahang","Malaysia","MY",{"type":49,"coordinates":68},[69,70],103.326,3.8077,{"lat":70,"lon":69},[73,77],{"name":74,"role":35,"phone":75,"phoneExt":10,"email":76},"Sin Nee Tan","+6095572222","christine0507@live.com",{"name":74,"role":32,"phone":10,"phoneExt":10,"email":10},{"facility":79,"status":45,"city":80,"state":81,"zip":10,"country":65,"countryCode":66,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Hospital Wanita dan Kanak-Kanak Sabah","Kota Kinabalu","Sabah",{"type":49,"coordinates":83},[84,85],116.0724,5.9749,{"lat":85,"lon":84},[88,92],{"name":89,"role":35,"phone":90,"phoneExt":10,"email":91},"Seng Wee Cheo","+6088522600","cheosengwee@gmail.com",{"name":89,"role":32,"phone":10,"phoneExt":10,"email":10},{"facility":94,"status":45,"city":95,"state":10,"zip":10,"country":65,"countryCode":66,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"Universiti Malaya Medical Centre","Kuala Lumpur",{"type":49,"coordinates":97},[98,99],101.68653,3.1412,{"lat":99,"lon":98},[102,103],{"name":30,"role":35,"phone":36,"phoneExt":10,"email":37},{"name":104,"role":32,"phone":10,"phoneExt":10,"email":10},"Mau Ern Poh",{"type":32,"investigatorFullName":106,"investigatorTitle":107,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Poh Mau Ern","Professor Dr","100621359",false,"NCT07369596","Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations","Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations: A Retrospective Cohort Study.","Inclusion Criteria:\n\n* Age ≥65 years\n* Histologically confirmed stage IV NSCLC\n* Negative for EGFR mutation, ALK rearrangement, and ROS1 fusion\n* Treated with at least ONE cycle of first-line chemotherapy\n\nExclusion Criteria:\n\n* Patients who received targeted therapy or immunotherapy as monotherapy in the first-line setting\n* Incomplete survival data","ALL","65 Years",{"count":117,"type":118},150,"ESTIMATED","OBSERVATIONAL","Evidence suggests that appropriately selected older adults can tolerate standard-dose chemotherapy and achieve survival outcomes comparable to younger patients. However, older adults are usually under-represented in clinical trials and often receive reduced doses of chemotherapy due to concerns regarding age-related frailty, polypharmacy, and toxicity.\n\nThis study seeks to evaluate chemotherapy dosing patterns and associated survival outcomes in older patients.",[122],"Non Small Cell Lung Carcinoma NSCLC",[124,125,126],"NSCLC","older patients","chemotherapy","2026-05-30",{"date":129,"type":130},"2026-06-02","ACTUAL",{"date":132,"type":130},"2026-01-01",{"date":134,"type":118},"2026-12-31",{"name":5,"class":6},4]